FY2025 EPS Forecast for Halozyme Therapeutics Cut by Analyst

Key Points

• Analyst D. Risinger from Leerink Partners has revised Halozyme Therapeutics' FY2025 EPS forecast down to $5.72 from $5.73, despite a current consensus estimate of $4.73 per share.
• Halozyme's stock fell 3.8% recently, now trading at $68.98, with analysts providing varied ratings including one Strong Buy and five Buy ratings.
• Recent insider trading saw Director Bernadette Connaughton and CFO Nicole Labrosse selling shares, leading to a decrease in ownership for both individuals following their transactions.

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2025 EPS estimates for shares of Halozyme Therapeutics in a note issued to investors on Wednesday, October 1st. Leerink Partnrs analyst D. Risinger now expects that the biopharmaceutical company will post earnings per share of $5.72 for the year, down from their prior forecast of $5.73. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share.

HALO has been the topic of a number of other research reports. Wall Street Zen lowered Halozyme Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, September 5th. Benchmark increased their price objective on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a report on Wednesday, September 24th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the stock an "overweight" rating in a research note on Monday, August 18th. JPMorgan Chase & Co. upped their price target on shares of Halozyme Therapeutics from $60.00 to $63.00 and gave the stock a "neutral" rating in a research report on Thursday, August 7th. Finally, HC Wainwright lifted their price objective on Halozyme Therapeutics from $85.00 to $90.00 and gave the stock a "buy" rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, five have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and an average target price of $70.44.

Halozyme Therapeutics Stock Down 3.8%

Shares of HALO opened at $68.98 on Monday. The firm has a market cap of $8.07 billion, a P/E ratio of 15.78, a PEG ratio of 0.37 and a beta of 1.16. Halozyme Therapeutics has a 12 month low of $42.01 and a 12 month high of $79.50. The stock's 50 day moving average is $70.45 and its two-hundred day moving average is $61.93. The company has a current ratio of 8.36, a quick ratio of 7.01 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The firm had revenue of $325.72 million for the quarter, compared to analysts' expectations of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.The company's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm earned $0.91 EPS. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HALO. DLD Asset Management LP acquired a new stake in shares of Halozyme Therapeutics in the second quarter valued at $650,250,000. Arrowstreet Capital Limited Partnership grew its position in Halozyme Therapeutics by 127.8% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,541,181 shares of the biopharmaceutical company's stock valued at $132,192,000 after acquiring an additional 1,425,674 shares in the last quarter. Qube Research & Technologies Ltd acquired a new position in Halozyme Therapeutics in the 2nd quarter valued at about $51,295,000. Los Angeles Capital Management LLC increased its stake in Halozyme Therapeutics by 951.8% during the second quarter. Los Angeles Capital Management LLC now owns 973,670 shares of the biopharmaceutical company's stock worth $50,650,000 after purchasing an additional 881,094 shares during the period. Finally, Norges Bank acquired a new stake in shares of Halozyme Therapeutics during the second quarter worth about $45,027,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $75.24, for a total transaction of $150,480.00. Following the completion of the sale, the director directly owned 44,952 shares in the company, valued at $3,382,188.48. This trade represents a 4.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Nicole Labrosse sold 2,227 shares of the business's stock in a transaction that occurred on Monday, September 22nd. The shares were sold at an average price of $77.95, for a total transaction of $173,594.65. Following the completion of the sale, the chief financial officer directly owned 22,079 shares in the company, valued at $1,721,058.05. This trade represents a 9.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 128,227 shares of company stock valued at $8,908,195. 2.90% of the stock is currently owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.